Pfizer Inc.  

(Public, NYSE:PFE)   Watch this stock  
Find more results for PFE
-0.05 (-0.14%)
Jan 19 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 36.50 - 37.28
52 week 30.90 - 37.37
Open 37.19
Vol / Avg. 29.54M/16.74M
Mkt cap 220.19B
P/E 22.69
Div/yield 0.34/3.68
EPS 1.63
Shares 5.96B
Beta 1.01
Inst. own 73%
Jan 30, 2018
Q4 2017 Pfizer Inc Earnings Call - 10:00AM EST - Add to calendar
Jan 30, 2018
Q4 2017 Pfizer Inc Earnings Release - 9:30AM EST - Add to calendar
Jan 8, 2018
Pfizer Inc at JPMorgan Healthcare Conference - Webcast
Oct 31, 2017
Q3 2017 Pfizer Inc Earnings Call - Webcast
Oct 31, 2017
Q3 2017 Pfizer Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Oct '17) 2016
Net profit margin 21.70% 13.68%
Operating margin 27.37% 17.05%
EBITD margin - 39.41%
Return on average assets 6.73% 4.26%
Return on average equity 19.13% 11.59%
Employees 96,500 -
CDP Score - B


235 E 42ND ST
NEW YORK, NY 10017-5703
United States - Map
+1-212-5732323 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia


Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines, as well as products for consumer healthcare. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, rare diseases and consumer healthcare. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. Its brands include Prevnar 13, Xeljanz, Eliquis, Lipitor, Celebrex, Pristiq and Viagra.

Officers and directors

Ian C. Read Chairman of the Board, Chief Executive Officer
Age: 63
Bio & Compensation  - Reuters
Frank A. D'Amelio Chief Financial Officer, Executive Vice President - Business Operations
Age: 59
Bio & Compensation  - Reuters
Mikael Dolsten M.D., Ph.D. President - Worldwide Research and Development
Age: 58
Bio & Compensation  - Reuters
Angela Hwang Group President - Pfizer Essential Health
Age: 52
Bio & Compensation  - Reuters
John D. Young Group President - Pfizer Innovative Health and Angela Hwang
Age: 53
Bio & Compensation  - Reuters
Albert Bourla Chief Operating Officer
Age: 56
Bio & Compensation  - Reuters
Rady A. Johnson II Executive Vice President, Chief Compliance and Risk Officer
Age: 55
Bio & Compensation  - Reuters
Douglas M. Lankler Executive Vice President, General Counsel
Age: 51
Bio & Compensation  - Reuters
Charles H. Hill III Executive Vice President - Worldwide Human Resources
Age: 61
Bio & Compensation  - Reuters
Freda C. Lewis-Hall M.D. Executive Vice President, Chief Medical Officer
Age: 62
Bio & Compensation  - Reuters